Biblio Discovery — Demo Discovery Service

4 hasil untuk "Lisa Werr"

Menampilkan 1–4 · 0,56 detik · RSS

  1. Artikel Jurnal

    Telomere maintenance mechanisms in neuroblastoma: New insights and translational implications

    Lisa Werr; Carolina Rosswog; Christoph Bartenhagen dkk.

    EJC Paediatric Oncology, Vol. 3 · 2024 · Inggris · DOAJ Scopus

    The clinical behaviour of neuroblastoma ranges from spontaneous tumour regression or maturation into benign ganglioneuroma to fatal progression despite intensive treatment [1,2]. The mechanisms underlying the distinct phenotypes have remained uncertain yet. A number of recent studies noticed that…

  2. Artikel Jurnal

    Reliable assessment of telomere maintenance mechanisms in neuroblastoma

    Alina Meeser; Christoph Bartenhagen; Lisa Werr dkk.

    Cell & Bioscience, Vol. 12 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Background Telomere maintenance mechanisms (TMM) are a hallmark of high-risk neuroblastoma, and are conferred by activation of telomerase or alternative lengthening of telomeres (ALT). However, detection of TMM is not yet part of the clinical routine, and consensus on TMM detection…

  3. Artikel Jurnal

    Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment

    Stefanie Höppner; Lisa Werr; Beata Szilagyi dkk.

    OncoImmunology, Vol. 15 No. 1 · 2026 · Inggris · DOAJ Scopus

    Telomerase is active in the majority of high-risk neuroblastomas, a pediatric tumor associated with poor patient outcomes. In other cancer types, resistance to immune checkpoint blockade was overcome by induction of telomere dysfunction using the telomerase substrate precursor…

  4. Artikel Jurnal

    Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma

    Lisa Werr; Jana Boland; Josephine Petersen dkk.

    The Journal of Clinical Investigation, Vol. 136 No. 7 · 2026 · Inggris · DOAJ Scopus

    Fibroblast growth factor receptor 1 (FGFR1) is recurrently mutated at p.N546 in neuroblastoma. We examined whether mutant FGFR1 is an oncogenic driver, a predictive biomarker, and an actionable vulnerability in this malignancy. FGFR1 mutations at p.N546 were associated with high-risk disease and…